The goal here is no longer rapid replenishment but steady upkeep
Tougas G, Chen Y, Coates G, Paterson W, Dallaire C, Par P, et al
In a specific trial, it was found that 10% of individuals who were taking semaglutide reported experiencing burping or eructation, whereas only 1% of those on the placebo reported similar symptoms
In traditional clinical trials, a "responder" is someone who loses at least 5% of their body weight within the first three to six months
Relapse prevention includes supporting digestive function, rebuilding the microbiome, improving motility and addressing nervous system dysregulation
We are talking about the following: Even though retatrutides main task is to affect appetite-regulating hormones, which begins almost immediately after therapy starts, most patients require time to see the first signs of improvement